Navigation Links
First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008
Date:3/24/2009

en's University Belfast)
  • Project dedicated to assessing civil conflict risks (Universitat Autonoma of Barcelona)
  • Project entitled A structural approach to inflation and term structure (EDHEC Business School of Lille)
  • 58 young researchers of promise, working in 13 countries

    • 28 postdoctoral fellowships of Euro 60,000 each
    • 30 doctoral fellowships of Euro 120,000 each

    "The AXA Research Fund chose to help outstanding institutions widen their reach in a sustainable manner, through capital endowments, a tool that is very new to Western Europe," said Ezra Suleiman, president of the Scientific Board. "We wanted to guarantee absolute independence and freedom to the researchers who receive our funding, since they are critical to success. We plan to pursue our action in 2009, and will bolster the international dimension of our investments."

    Information about the AXA Research Fund, in particular that pertaining to the selection criteria and process for researchers and institutions interested in being considered for financial assistance can be found at our website: http://researchfund.axa.com

    About AXA

    AXA Group is a worldwide leader in Financial Protection. AXA's operations are diverse geographically, with major operations in Europe, North America and the Asia/Pacific area. For full year 2008, IFRS revenues amounted to Euro 91.2 billion and IFRS adjusted earnings to Euro 3.7 billion. AXA had Euro 981 billion in assets under management as of December 31, 2008.

    The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISIN FR0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA). The American Depository Share is also listed on the NYSE under the
    '/>"/>

    SOURCE AXA Group
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
    2. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
    3. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
    4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
    5. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
    6. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
    7. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
    8. Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
    9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
    10. First U.S. Patients Enrolled in the REALISM Continued Access Study
    11. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... 2, 2014   Intrexon Corporation (NYSE: ... announced that it has entered into an Exclusive Channel ... of Sanofi (EURONEXT: SAN and NYSE: SNY ... specific family of its marketed Active Pharmaceutical Ingredients (APIs) ... . This collaboration will leverage Intrexon,s proprietary technology ...
    (Date:9/2/2014)... Cepheid (NASDAQ: CPHD) announced today the release ... molecular test for rapid, accurate and reliable determination ... RSV infection. The test will be marketed as ... In Vitro Diagnostic Medical Devices, bringing ... Xpert Flu/RSV XC runs on Cepheid,s GeneXpert ® ...
    (Date:9/2/2014)... -- Sinovac Biotech Ltd. (NASDAQ: SVA ), a leading ... today announced that the Company,s management will participate in the ... Global Healthcare Conference, to be held at the Grand Hyatt ... Morgan Stanley Asia Pacific Healthcare Day, to be held at ... Aegis Healthcare & Technology Conference, to be held at the ...
    Breaking Medicine Technology:Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 2Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 3Cepheid Announces European Release of Xpert Flu/RSV XC for Accurate and Reliable Detection and Differentiation of Flu A, Flu B, and RSV Infection 4Sinovac to Participate in Upcoming Investor Conferences 2
    ... 28, 2011 Burg Simpson Eldredge Hersh & Jardine, P.C., ... delighted to announce that shareholder, Seth. A. Katz, has been ... a member of the Plaintiffs, Steering Committee in the multidistrict litigation ... ASR XL Acetabular Hip System. In August 2010, ...
    ... 28, 2011 Awarepoint Corporation, a privately held ... with 91 hospital sites contracted consisting of 45,062,013 ... network coverage in U.S. hospitals and 135,265 healthcare ... enterprise-wide U.S. hospital client base for RTLS in ...
    Cached Medicine Technology:Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 2Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 3Awarepoint Announces RTLS in Healthcare Leadership with 2010 Results 4
    (Date:9/2/2014)... key to more youthful immune function might already be ... the Journal of Leukocyte Biology ... mice had different responses to Mycobacterium tuberculosis ... reversed by ibuprofen. , "Inflammation in old age can ... Ph.D., a researcher involved in the work from the ...
    (Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
    (Date:9/2/2014)... 2014 Nanomedicine is essentially based ... treating and/or prevention of diseases and infections. Nanotechnology-based ... neurological, and oncology diseases. , Nanomedicine is ... various nanoparticles, their medical usages, and their actions ... scope for research in this domain, and scientists ...
    (Date:9/2/2014)... September 02, 2014 On Saturday, September 6, ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Kiest Park Recreation ... to 1:00 pm. , “Since 2007, we have partnered ...
    (Date:9/2/2014)... Durable Medical Goods manufacture ThermoTek , announced ... company LeaseQ, Inc. to help customers acquire capital goods ... LeaseQ’s breakthrough finance shopping platform has enabled businesses to ... run their business. , Said LeaseQ Vice President ... sales team to provide customers faster access to capital ...
    Breaking Medicine News(10 mins):Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Technology Manufacturer ThermoTek Announces New Partnership with LeaseQ.com to Help More Customers Acquire Equipment Faster and Cheaper 2
    ... have found out the benefits of oral ZYVOX for ... bacterial infections. They compared data from 80 health care ... of Intravenous Vancomycin. The results show that oral tablets ... of money spent to health clinics compared to vancomycin. ...
    ... from Children’s Hospital of Boston have reconstructed defective ... researchers used amniotic fluid for growing the sections ... living tissues into lambs, while they were in ... used for altering birth defects. Undifferentiated stem cell ...
    ... a life of dignity with access to medicines and care ... cancer, say experts on the eve of World Hospice and ... states like Kerala, Maharashtra, Karnataka and Orissa as well as ... administer strong pain killers that make life more bearable., ...
    ... is calling for concerted action following the recent release ... (WHO). // ,"Preventing Chronic Diseases: A ... global burden of chronic diseases including cardiovascular disease, cancer, ... global action to prevent chronic disease could save the ...
    ... total abdominal hysterectomy and laparoscopically assisted vaginal hysterectomy ... the advantages of lower morbidity // and faster ... vaginal route, although there is a high feasibility ... gynecologists need to be familiar with surgical techniques. ...
    ... and obstructive sleep apnea share some common symptoms, due to ... diagnosis. Obstructive sleep apnea (OSA) occurs when the tongue or ... the airway. This can happen more than 50 times an ... last as long as 60 seconds. The problem is twice ...
    Cached Medicine News:Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2Health News:Terminally Ill deserves a better quality of Life 2Health News:Terminally Ill deserves a better quality of Life 3Health News:Reversibility of symptoms of depression using CPAP in patients with obstructive sleep apnea 2
    Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
    ... is a new, portable, light weight, high ... dermatology, cosmetic and plastic surgery, general surgery, ... skin resurfacing, it is the smallest, yet ... the market. It provides an ideal treatment ...
    ... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
    ... biolitecs sophisticated Ceralas D15/810 diode laser is ... ideal for many soft tissue applications. With ... D15/810 features a flexible fiber optic delivery ... irrigated or dry environments alike.,Compact and portable, ...
    Medicine Products: